Ani Pharmaceuticals (ANIP) Debt to Equity (2017 - 2025)
Historic Debt to Equity for Ani Pharmaceuticals (ANIP) over the last 11 years, with Q3 2025 value amounting to $0.62.
- Ani Pharmaceuticals' Debt to Equity fell 125.23% to $0.62 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.62, marking a year-over-year decrease of 125.23%. This contributed to the annual value of $0.79 for FY2024, which is 3643.99% up from last year.
- Ani Pharmaceuticals' Debt to Equity amounted to $0.62 in Q3 2025, which was down 125.23% from $0.72 recorded in Q2 2025.
- Ani Pharmaceuticals' Debt to Equity's 5-year high stood at $1.07 during Q2 2021, with a 5-year trough of $0.58 in Q4 2023.
- For the 5-year period, Ani Pharmaceuticals' Debt to Equity averaged around $0.76, with its median value being $0.73 (2022).
- As far as peak fluctuations go, Ani Pharmaceuticals' Debt to Equity tumbled by 3197.14% in 2022, and later surged by 3643.99% in 2024.
- Quarter analysis of 5 years shows Ani Pharmaceuticals' Debt to Equity stood at $0.74 in 2021, then decreased by 4.26% to $0.71 in 2022, then decreased by 18.54% to $0.58 in 2023, then skyrocketed by 36.44% to $0.79 in 2024, then fell by 21.54% to $0.62 in 2025.
- Its last three reported values are $0.62 in Q3 2025, $0.72 for Q2 2025, and $0.76 during Q1 2025.